Lecithin

Diet and Nutrition

Diabetes

Cardiac Procedures

Cardiology

Exercise

Smoking Cessation

Back to Original List
Principal Proposed UsesOther Proposed Uses


Related Terms

  • Egg Lecithin
  • Phosphatidylcholine in Lecithin
  • Soy Lecithin

Uses

Principal Proposed Uses

  • None

Other Proposed Uses

For decades, lecithin has been a popular treatment for high cholesterol (although there is surprisingly little evidence that it works). More recently, lecithin has been proposed as a remedy for various psychological and neurological diseases, such as Tourette's syndrome, Alzheimer's disease, and bipolar disorder (also known as manic depression).
Lecithin contains a substance called phosphatidylcholine (PC) that is presumed to be responsible for its medicinal effects. Phosphatidylcholine is a major part of the membranes surrounding our cells. However, when you consume this substance it is broken down into the nutrient choline rather than being carried directly to cell membranes. Choline acts like folate, TMG (trimethylglycine), and SAMe (S-adenosylmethionine) to promote methylation. (See the article on TMG for further discussion of this subject.) It is also used to make acetylcholine , a nerve chemical essential for proper brain function.
This article discusses lecithin and phosphatidylcholine. For more information on the effects and possible benefits of Choline alone, see the full article on that subject.

Sources

Neither lecithin nor its ingredient phosphatidylcholine is an essential nutrient; however, choline has recently been recognized as essential. For use as a supplement or a food additive, lecithin is often manufactured from soy.

Therapeutic Dosages

Ordinary lecithin contains about 10% to 20% phosphatidylcholine. However, European research has tended to use products concentrated to contain 90% phosphatidylcholine in lecithin, and the following dosages are based on that type of product. For psychological and neurological conditions, doses as high as 5 to 10 g taken three times daily have been used in studies. For liver disease, a typical dose is 350 to 500 mg taken three times daily; for high cholesterol, 500 to 900 mg taken three times daily has been tried.

Therapeutic Uses

For a while, lecithin/phosphatidylcholine was one of the most commonly recommended natural treatments for high cholesterol . However, this idea appears to rest entirely on studies of unacceptably low quality. 2,25 The best designed studies have failed to find any evidence of benefit. 3,25-28
In Europe, phosphatidylcholine is also used to treat liver diseases , such as alcoholic fatty liver, alcoholic hepatitis , liver cirrhosis , and viral hepatitis . However, research into these potential uses remains preliminary and has yielded contradictory results. 4-14 Lecithin may help to prevent the development of gallstones . 32
Researchers have recently become interested in the use of phosphadylcholine as a supportive treatment in severe ulcerative colitis . There may be an insufficient quantity of phosphatidylcholine in the mucus lining the colon in patients with ulcerative colitis. Taking phosphatidylcholine may correct this deficiency. A small double-blind, placebo controlled study of 60 patients whose ulcerative colitis was poorly responsive to corticosteroids were randomized to receive either phosphadylcholine (2 g per day) or placebo for 12 weeks. 31 Half of the participants taking phosphadylcholine showed a significant improvement in symptoms versus only 10% taking placebo. Moreover, 80% taking phosphadylcholine were able to completely discontinue their corticosteroids without disease flare-up compared to 10% taking placebo. Along the same line, a study involving 60 people with ulcerative colitis found phosphadylcholine to be effective in reducing the need for corticosteroids. 35 Doses of 3 to 4 g seems to be the most helpful for achieving remission. 33
Some evidence hints that phosphatidylcholine may reduce homocysteine levels , which in turn was for a time thought likely to reduce heart disease risk. 29
Because phosphatidylcholine plays a role in nerve function, it has also been suggested as a treatment for various psychological and neurological disorders, such as Alzheimer's disease , bipolar disorder , Parkinson's disease , Tourette's syndrome, and tardive dyskinesia (a late-developing side effect of drugs used for psychosis). However, the evidence that it works is limited to small studies with conflicting results. 15-24,30
Lipolysis involves the removal of unwanted fat cells by injecting phosphatidylcholine and another substance (sodium deoxycholate) into the fat. Phosphatidylcholine appears to be effective for this purpose. 34

Safety Issues

Lecithin is believed to be generally safe. However, some people taking high dosages (several grams daily) experience minor but annoying side effects, such as abdominal discomfort, diarrhea, and nausea. Maximum safe dosages for young children, pregnant or nursing women, or those with severe liver or kidney disease have not been determined.

References

1 Brook JG, Linn S, Aviram M. Dietary soya lecithin decreases plasma triglyceride levels and inhibits collagen- and ADP-induced platelet aggregation. Biochem Med Metab Biol . 1986;35:31-39.

2 Wojcicki J, Pawlik A, Samochowiec L, et al. Clinical evaluation of lecithin as a lipid-lowering agent. Phytother Res . 1995;9:597-599.

3 Oosthuizen W, Vorster HH, Vermaak, WJ, et al. Lecithin has no effect on serum lipoprotein, plasma fibrinogen and macro molecular protein complex levels in hyperlipidaemic men in a double-blind controlled study. Eur J Clin Nutr . 1998;52:419-424.

4 Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology . 1992;102:1363-1370.

5 Guan R, Ho KY, Kang JY, et al. The effect of polyunsaturated phosphatidyl choline in the treatment of acute viral hepatitis. Ailment Pharmacol Ther . 1995;9:699-703.

6 Lieber CS, Robins SJ, Li J, et al. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology . 1994;106:152-159.

7 Lieber CS, DeCarli LM, Mak KM, et al. Attenuation of alcohol-induced hepatic fibrosis by polyunsaturated lecithin. Hepatology . 1990;12:1390-1398.

8 Lieber CS, Leo MA, Mak KM, et al. Choline fails to prevent liver fibrosis in ethanol-fed baboons but causes toxicity. Hepatology . 1985;5:561-572.

9 Lieber CS, Rubin E. Alcoholic fatty liver. N Engl J Med . 1969;280:705-708.

10 Schuller-Perez A, Gonzalez San Martin F. A controlled study with polyunsaturated phosphatidylcholine compared to placebo in alcoholic steatosis of the liver [translated from German]. Med Welt . 1985;36:517-521.

11 Knuchel F. Double-blind study in patients with alcoholic toxic fatty liver. Effect of essential phospholipids on enzyme behavior and lipid composition of the serum [translated from German]. Med Welt . 1979;30:411-416.

12 Jenkins PJ, Portmann BP, Eddleston AL, et al. Use of polyunsaturated phosphatidylcholine in HBsAg negative chronic active hepatitis: results of prospective double-blind controlled trial. Liver . 1982;2:77-81.

13 Niederau C, Strohmeyer G, Heintges T, et al. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Hepatogastroenterology. 1998;45:797-804.

14 Singh NK, Prasad RC. A pilot study of polyunsaturated phosphatidyl choline in fulminant and subacute hepatic failure. J Assoc Physicians India. 1998;46:530-532.

15 Stoll AL, Sachs GS, Cohen BM, et al. Choline in the treatment of rapid-cycling bipolar disorder: clinical and neurochemical findings in lithium-treated patients. Biol Psychiatry . 1996;40:382-388.

16 Cohen BM, Lipinski JF, Altesman RI. Lecithin in the treatment of mania: Double-blind, placebo-controlled trials. Am J Psychiatry . 1982;139:1162-1164.

17 Polinsky RJ, Ebert MH, Caine ED, et al. Cholinergic treatment in the Tourette syndrome. N Engl J Med . 1980;302:1310.

18 Gelenberg AJ, Dorer DJ, Wojcik JD, et al. A crossover study of lecithin treatment of tardive dyskinesia. J Clin Psychiatry . 1990;51:149-153.

19 Domino EF, May WW, Demetriou S, et al. Lack of clinically significant improvement of patients with tardive dyskinesia following phosphatidylcholine therapy. Biol Psychiatry . 1985;20:1189-1196.

20 Weintraub S, Mesulan MM, Auty R, et al. Lecithin in the treatment of Alzheimer's disease. Arch Neurol . 1983;40:527-528.

21 Cohen BM, Miller AL, Lipinski JF, et al. Lecithin in mania: a preliminary report. Am J Psychiatry . 1980;137:242-243.

22 Cohen BM, Lipinski JF, Altesman RI. Lecithin in the treatment of mania: Double-blind, placebo-controlled trials. Am J Psychiatry . 1982;139:1162-1164.

23 Harris CM, Dysken MW, Fovall P, et al. Effect of lecithin on memory in normal adults. Am J Psychiatry. 1983;140:1010-1012.

24 Joe SH. Effect of lecithin on tardive dyskinesia. Korea Univ Med J. 1985;22:197-206.

25 Knuiman JT, Beynen AC, Katan MB. Lecithin intake and serum cholesterol. Am J Clin Nutr . 1989;49:266-268.

26 Greten H, et al. The effect of polyunsaturated phosphatidylcholine on plasma lipids and fecal sterol excretion. Atherosclerosis . 1980;36:81-88.

27 Childs MT, et al. The contrasting effects of a dietary soya lecithin product and corn oil on lipoprotein lipids in normolipidemic and familial hypercholesterolemic subjects. Atherosclerosis . 198;38:217-228.

28 Kesaniemi YA, et al. Effects of dietary polyenylphosphatidylcholine on metabolism of cholesterol and triglycerides in hypertriglyceridemic patients. Am J Clin Nutr. 1986;43:98-107.

29 Olthof MR, Brink EJ, Katan MB, et al. Choline supplemented as phosphatidylcholine decreases fasting and postmethionine-loading plasma homocysteine concentrations in healthy men. Am J Clin Nutr. 2005;82:111-117.

30 Higgins JPT, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev. 2003;(3):CD001015.

31 Stremmel W, Ehehalt R, Autschbach F, et al. Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med. 2007;147:603-610.

32 Gaby AR. Nutritional approaches to prevention and treatment of gallstones. Altern Med Rev. 2009;14(3):258-267.

33 Stremmel W, Braun A, Hanemann A, Ehehalt R, Autschbach F, Karner M. Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study. J Clin Gastroenterol. 2010;44(5):e101-7.

34 Salti G, Ghersetich I, Tantussi F, Bovani B, Lotti T. Phosphatidylcholine and sodium deoxycholate in the treatment of localized fat: a double-blind, randomized study. Dermatol Surg. 2008;34(1):60-66.

35 Stremmel W, Ehehalt R, Autschbach F, Karner M. Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med. 2007;147(9):603-610.

Revision Information

This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.

Copyright © EBSCO Publishing
All rights reserved.